| Literature DB >> 33574291 |
Zuzana Kos1, Elvire Roblin2,3, Rim S Kim4, Stefan Michiels2,3, Brandon D Gallas5, Weijie Chen5, Koen K van de Vijver6,7, Shom Goel8,9, Sylvia Adams10, Sandra Demaria11, Giuseppe Viale12, Torsten O Nielsen13, Sunil S Badve14, W Fraser Symmans15, Christos Sotiriou16, David L Rimm17, Stephen Hewitt18, Carsten Denkert19, Sibylle Loibl20, Stephen J Luen9,21, John M S Bartlett22,23, Peter Savas9,21, Giancarlo Pruneri24, Deborah A Dillon25,26, Maggie Chon U Cheang27, Andrew Tutt28, Jacqueline A Hall29, Marleen Kok30, Hugo M Horlings6,31, Anant Madabhushi32,33, Jeroen van der Laak34, Francesco Ciompi34, Anne-Vibeke Laenkholm35, Enrique Bellolio36, Tina Gruosso37, Stephen B Fox8,38, Juan Carlos Araya39, Giuseppe Floris40, Jan Hudeček41, Leonie Voorwerk42, Andrew H Beck43, Jen Kerner43, Denis Larsimont44, Sabine Declercq45, Gert Van den Eynden45, Lajos Pusztai46, Anna Ehinger47, Wentao Yang48, Khalid AbdulJabbar49, Yinyin Yuan49, Rajendra Singh50, Crispin Hiley51, Maise Al Bakir51, Alexander J Lazar52, Stephen Naber53, Stephan Wienert54, Miluska Castillo55, Giuseppe Curigliano56, Maria-Vittoria Dieci57,58, Fabrice André59, Charles Swanton51,60, Jorge Reis-Filho61,62, Joseph Sparano63, Eva Balslev64, I-Chun Chen65,66,67, Elisabeth Ida Specht Stovgaard64, Katherine Pogue-Geile4, Kim R M Blenman46, Frédérique Penault-Llorca68, Stuart Schnitt25, Sunil R Lakhani69, Anne Vincent-Salomon70, Federico Rojo71,72, Jeremy P Braybrooke73, Matthew G Hanna61, M Teresa Soler-Monsó74, Daniel Bethmann75, Carlos A Castaneda55, Karen Willard-Gallo76, Ashish Sharma77, Huang-Chun Lien78, Susan Fineberg79, Jeppe Thagaard80, Laura Comerma72,81, Paula Gonzalez-Ericsson82, Edi Brogi61, Sherene Loi9,21, Joel Saltz83, Frederick Klaushen84, Lee Cooper85, Mohamed Amgad86, David A Moore87,88, Roberto Salgado21,45.
Abstract
Stromal tumor-infiltrating lymphocytes (sTILs) are important prognostic and predictive biomarkers in triple-negative (TNBC) and HER2-positive breast cancer. Incorporating sTILs into clinical practice necessitates reproducible assessment. Previously developed standardized scoring guidelines have been widely embraced by the clinical and research communities. We evaluated sources of variability in sTIL assessment by pathologists in three previous sTIL ring studies. We identify common challenges and evaluate impact of discrepancies on outcome estimates in early TNBC using a newly-developed prognostic tool. Discordant sTIL assessment is driven by heterogeneity in lymphocyte distribution. Additional factors include: technical slide-related issues; scoring outside the tumor boundary; tumors with minimal assessable stroma; including lymphocytes associated with other structures; and including other inflammatory cells. Small variations in sTIL assessment modestly alter risk estimation in early TNBC but have the potential to affect treatment selection if cutpoints are employed. Scoring and averaging multiple areas, as well as use of reference images, improve consistency of sTIL evaluation. Moreover, to assist in avoiding the pitfalls identified in this analysis, we developed an educational resource available at www.tilsinbreastcancer.org/pitfalls .Year: 2020 PMID： 33574291 DOI： 10.1038/s41523-020-0156-0
Source DB: PubMed Journal: NPJ Breast Cancer ISSN： 2374-4677